![]() |
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
Sponsored by: |
AstraZeneca |
---|---|
Information provided by: | AstraZeneca |
ClinicalTrials.gov Identifier: | NCT00061022 |
This study will determine if NXY-059 will improve recovery from an acute stroke. The study is designed to look at both overall recovery and recovery of motor function, for example muscle strengthen and coordination.
Condition | Intervention | Phase |
---|---|---|
Cerebral Stroke Stroke, Acute Cerebrovascular Stroke Ischemic Attack, Transient |
Drug: NXY-059 |
Phase II Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Factorial Assignment, Safety/Efficacy Study |
Official Title: | SAINT (Stroke - Acute Ischemic - NXY Treatment) A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIb/III Study to Assess the Efficacy and Safety of Intravenous NXY-059 in Acute Ischemic Stroke |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | AstraZeneca NXY-059 Medical Science Director, MD | AstraZeneca |
Study ID Numbers: | SA-NXY-0007, 007, SAINT 2 |
Study First Received: | May 20, 2003 |
Last Updated: | November 1, 2006 |
ClinicalTrials.gov Identifier: | NCT00061022 |
Health Authority: | United States: Food and Drug Administration |
Stroke cerebral vascular accident CVA Ischemia Hemorrhage |
TIA Transient Ischemic Attack Brain Attack Cataplexy |
Ischemic Attack, Transient Cerebral Infarction Stroke Vascular Diseases Disufenton sodium Central Nervous System Diseases Ischemia |
Hemorrhage Brain Diseases Cerebrovascular Disorders Cataplexy Brain Ischemia Brain Infarction Infarction |
Antioxidants Pathologic Processes Molecular Mechanisms of Pharmacological Action Therapeutic Uses Physiological Effects of Drugs |
Nervous System Diseases Cardiovascular Diseases Cardiovascular Agents Protective Agents Pharmacologic Actions |